Clinical anticancer drug development: targeting the cyclin-dependent kinases.
Cell division involves a cyclical biochemical process composed of several step-wise reactions that have to occur once per cell cycle. Dysregulation of cell division is a hallmark of all cancers. Genetic and epigenetic mechanisms frequently result in deranged expression and/or activity of cell-cycle proteins including the cyclins, cyclin-dependent kinases (Cdks), Cdk inhibitors and checkpoint control proteins. The critical nature of these proteins in cell cycling raises hope that targeting them may result in selective cytotoxicity and valuable anticancer activity.
Benson
C
C
Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, Institute for Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.
Kaye
S
S
Workman
P
P
Garrett
M
M
Walton
M
M
de Bono
J
J
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D016503:Drug Delivery Systems; D015195:Drug Design; D013678:Technology, Pharmaceutical
D000970:Antineoplastic Agents; D018844:Cyclin-Dependent Kinases